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Various tissue-speciﬁc antibodies have been attached to nanoparticles to obtain targeted delivery. In
particular, nanodelivery systems with selectivity for breast, prostate and cancer tissue have been
developed. Here, we have developed a nanodelivery system that targets the thyroid gland. Nano-
liposomes have been conjugated to the thyroid-stimulating hormone (TSH), which binds to the TSH
receptor (TSHr) on the surface of thyrocytes. The results indicate that the intracellular uptake of TSH-
nanoliposomes is increased in cells expressing the TSHr. The accumulation of targeted nanoliposomes
in the thyroid gland following intravenous injection was 3.5-fold higher in comparison to untargeted
nanoliposomes. Furthermore, TSH-nanoliposomes encapsulated with gemcitabine showed improved
anticancer efﬁcacy in vitro and in a tumor model of follicular thyroid carcinoma. This drug delivery
system could be used for the treatment of a broad spectrum of thyroid diseases to reduce side effects and
improve therapeutic efﬁcacy.
 2014 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/3.0/).1. Introduction
The ﬁeld of targeted therapy was born from the introduction of
the “magic bullet” concept, which entails the selective delivery of ances, University of Catanzaro
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Ltd. This is an open access article udrug to a tissue of interest [1]. The concept involves reducing side
effect, broadening the therapeutic window and increasing drug
efﬁcacy, through the selective delivery of an agent to a speciﬁc site
in the body. Such selectivity is especially desired for diseases
characterized by a low therapeutic index, such as cancer. Among
various approaches adopted for drug delivery [2e5], liposomes
provide a strategy for improving the biopharmaceutical properties
of drugs [6e8]. In particular, pegylated liposomes can avoid
immunological recognition and rapid clearance by macrophages
[9e11]. Accordingly, several liposomal formulations have gained
clinical approval and many more are currently undergoing clinical
trials [12]. In an attempt to achieve selectivity, antibodies that are
speciﬁc for surface molecules on target cells have been conjugated
to liposomes. For instance, an antibody fragment against thender the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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expressed in breast cancer, has been attached to liposomes [13].
Similarly, liposomes have been coated with the monoclonal anti-
body (mAb) 2C5, which binds to nucleosomes on the surface of
cancer cells [14]. In addition, folate-moieties have been incorpo-
rated in supramolecular vesicular aggregates to obtain preferential
uptake by cancer cells that express the folate receptor [15,16].
Although several tissue-speciﬁc antibodies have been conju-
gated to nanoparticles, there are several organs, such as the thyroid
gland, that have not been the focus of targeted drug delivery. We
propose a strategy for obtaining preferential accumulation of
nanoparticles in the thyroid. Thyroid-stimulating hormone (TSH)
has been attached to the surface of pegylated nanoliposomes with
the aim of targeting the TSH receptor (TSHr). The TSHr is a glyco-
protein G-protein-coupled receptor expressed in the plasma
membrane of thyrocytes. This receptor binds to TSH with high af-
ﬁnity and speciﬁcity and mediates the ligands biological effects on
the thyroid gland [17]. TSHr expression is maintained in most
thyroid pathologies, including benign and malignant tumors [18e
23]. More importantly, the receptor is also present in the majority
of less differentiated and more aggressive tumors [18e23], making
it an optimal target for the delivery of chemotherapeutics.
2. Materials and methods
2.1. Materials
1,2-dipalmitoyl-sn-glycero-3-phospocholine monohydrate (DPPC) and N-
(carbonyl-methoxypolyethylene glycol-2000)-1,2-distearoyl-sn-glycero-3-
phosphoethanolamine (DSPE-mPEG2000) were purchased from Genzyme (Suffolh,
UK). 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[PDP(methoxypoly-
ethylene glycol-2000)] (DSPE-mPEG2000-PDP) was obtained from Avanti Polar
(Alabaster, Alabama, USA). TSH (from human pituitary), N-(ﬂuorescein-5-
tiocarbamoyl)-1,2-dihexadecanoyl-sn-glycero-3-phosphoethanolamine triethy-
lammonium salt (ﬂuorescein-DHPE), 3-[4,5-dimethylthiazol-2-yl]-3,5-
diphenyltetrazolium bromide salt (tetrazolium salt) and dithiothreitol (DTT) were
purchased from Sigma Chemicals Co. (St. Louis, USA). F12-medium, minimum
essential medium (MEM) with glutamine, trypsin/ethylenediaminetetraacetic acid
(EDTA) solution (1), fetal bovine serum (FBS) and penicillinestreptomycin solution
were obtained from Gibco (Invitrogen Corporation, UK). [3H]-cholesteryl hexadecyl
ether ([3H]CHE, 40 Ci/mmol) was obtained from Perkin Elmer-Italia (Monza, Italy).
Chemicals, buffers, liquid chromatography-mass spectrometry (LC-MS)-gradewater,
formic acid, cholesterol and acetonitrile and proteomics grade trypsinwere obtained
from SigmaeAldrich (St. Louis, MO). Integra Frits 75 mm bore internal diameter
(ID), Pico Frits 50 mm ID and 10 mm tip ID were from New Objective (Cambridge,
MA). Microﬂow tees, PEEK unions and tees were from Upchurch Scientiﬁc (Oak
Harbor, WA). The stationary phase used for packing the nanoscale LC column was
3 mmC18 provided by Dr. Maisch (Entringen, Germany). Zip Tipswith strong cation
exchange (SCX) properties were purchased fromMillipore (Billerica, MA). Oasis HLB
1 cc (10 mg) solid phase extraction (SPE) cartridges were fromWaters (Milford, MA).
Gemcitabine (2,2I-diﬂuorodeoxycytidine) hydrochloride (HPLC purity >99%) was a
gift from Eli-Lilly Italia S.p.A. (Sesto Fiorentino, Firenze, Italy), and was used without
further puriﬁcation. FTC-133 human follicular thyroid carcinoma cells were pur-
chased from SigmaeAldrich (S.r.l. Milan, Italy) and Chinese hamster ovary (CHO)
cells were provided by ATCC (Teddington, Middlesex, UK).
2.2. Preparation of TSH-nanoliposomes
Nanoliposomes were made from DPPC/cholesterol/DSPEmPEG2000/DSPE-
mPEG2000-PDP (6:3:0.6:0.4 M ratio). The lipid mixture (20 mg) was dissolved in a
round-bottom ﬂask, using a chloroform/methanol mixture (3:1 v/v). Fluorescein-
labeled and radiolabelled nanoliposomes where obtained by adding ﬂuorescein-
DHPE (0.1% molar) or [3H]CHE to the lipid mixture. The organic solvents were
removed with a rotary evaporator (Büchi R-210 Switzerland), followed by overnight
incubation in a Büchi T51 glass-drying oven connected to a vacuum pump. Multi-
lamellar nanoliposomes were prepared by hydrating the lipid ﬁlm with 1 mL of
saline solution (NaCl 0.9% w/v) and performing three alternate cycles (3min each) of
heating at 58 C (water bath) and vortex mixing at 700 rpm. To reduce the disulﬁde
bond the nanoliposomes were incubated with a 50 mM DTT solution (1:2 v/v
respectively) for 30 min. Excess DTT was then removed after centrifugation at
20,000  g for 60 min at 4 C with a Beckman Coulter Allegra 64R centrifuge.
Successively, the pellet was resuspended in 250 mM ammonium sulfate solution
(1 mL) and subjected to ten cycles of freezing (liquid nitrogen) and thawing (water
bath at 40 C), thus achieving a pH gradient with an acid environment in the
aqueous compartment.The nanoliposomes were further extruded through polycarbonate ﬁlters with
pore sizes of 400 nm, 200 nm and 100 nm (Costar, Corning Incorporated, NY, USA)
using a stainless steel extrusion device (Lipex Biomembranes, Vancouver, BC, USA).
Unentrapped ammonium sulfate solution was removed by centrifugation. Gemci-
tabine loading was achieved by incubating nanoliposomes for 3 h at room tem-
perature in an isotonic solution (1 mL) of gemcitabine-hydrochloride (1 mM).
Unentrapped drug was removed by gel permeation chromatography. The 3-(2-
pyridyldithio)propionate (PDP) moieties on the liposomal surface were reduced
and conjugated to TSH (2.5 mg/mL nanoliposomes) through overnight incubation.
2.3. TSH-nanoliposome puriﬁcation
Unentrapped gemcitabine and unconjugated TSH were removed by gel
permeation chromatography using an ÄKTA prime PLUS (Amersham Biosciences,
Uppsala, Sweden), equipped with an UV detector at ﬁxed wavelengths (254 nm and
280 nm). The puriﬁcation procedure was performed at room temperature using a
XK16/20 column (Amersham Biosciences, Uppsala, Sweden) with Sephadex G-25 as
the stationary phase and a saline solution as the eluent. The column had an equil-
ibration volume of 80 mL and the ﬂow rate was 0.5 mL/min. The amount of unen-
trapped gemcitabine was determined spectrophotometrically with lmax
(wavelength) at 268.8 nm using a Perkin Elmer Lambda 20 UV-Vis spectropho-
tometer (Uberlingen, Germany) equipped with Perkin Elmer UV WinLab ver. 2.8
acquisition software (Uberlingen, Germany).
2.4. Sample preparation for liquid chromatography-tandem mass analysis
spectrometry
To obtain a reference value, human TSH (2.5 mg in 5 mL) was diluted with 20 mL of
digestion buffer composed of 0.2% (v/v) SDS and 200 mM tris(hydroxymethyl)ami-
nomethane (Tris, pH 8.5). The protein was reduced by adding 100 mM DTT (2.5 mL)
and incubating the mixture for 1 h at 37 C. Cysteines were then alkylated by adding
3 mL of 200 mM freshly prepared iodoacetamide solution inwater and incubating the
mixture for 1 h at 37 C. Finally, excess iodoacetamide was neutralized by adding
0.5 mL of 100 mM DTT. The solution was brought to a volume of 100 mL by adding LC
water, and trypsin was added (500 ng) to allow enzymatic digestion. Before per-
forming LC coupled to tandem MS (LC-MS/MS) analysis, 3 mL of digested TSH was
diluted with 27 mL of solution SCX1, composed of acetonitrile/water/formic acid
(80:19.9:0.1 v/v/v), and puriﬁed by ZipTips SCX following a slightly modiﬁed pro-
cedure, with respect to the manufacturer’s instructions. Brieﬂy, ZipTips were
equilibrated with solution SCX1 and then used to concentrate the peptide mixture
through at least ﬁve cycles of aspiration/discarding (aspiration volume 10 mL). After
510 mL washes with solution SCX1, the detergent-free peptide mixture was eluted
in 2 mL of water/methanol/ammonium hydroxide solution (80:15:5, v/v/v). The
sample was then diluted in 28 mL of loading pump solvent.
In order to evaluate whether the conjugation of TSH hormone with nano-
liposomes was successful, the formulation was washed three times and then incu-
bated with DTT (10 mM) and Tris (100 mM). The supernatants from the last wash
(control) and nanoliposomes incubated with DTT were analyzed. Proteins were
reduced, alkylated, and digested, as described in the section above. The samples
were concentrated by SPE. Brieﬂy, the SPE column (beads, 10 mg) was conditioned
with 500 mL of water/methanol 1/1 (v/v); the column was then equilibrated with
500 ml of water/methanol/triﬂuoroacetic acid (TFA) (97.9:2:0.1 v/v/v) (Wash RP1);
the peptide solution was then acidiﬁed to 0.5% (v/v) TFA and loaded onto the SPE
cartridge. After two consecutive 400 mL washes of Wash RP1 and a water/methanol/
formic acid mixture (97.9:2:0.1 v/v/v), peptides were eluted off the SPE cartridge
with 250 mL of water/methanol/formic acid (19.9:80:0.1 v/v/v). Samples were then
evaporated in a vacuum centrifuge, and reconstituted in 30 mL of loading pump
solvent.
2.5. LC-MS/MS analysis and database search
Chromatography was performed on an Ultimate Nano LC System from Dionex
(Sunnyvale, CA) using a valveless setup [24]. 10 mL of sample was loaded in an in-
house packed 75 mm ID, 4 cm long Integra Frit trapping column (1 cm packing
bed length) at 12 mL/min of loading pump solvent consisting of water/acetonitrile/
triﬂuoroacetic acid (TFA) (97.95:2:0.05 v/v/v). After 4 min of washing, the trapping
columnwas switched online to the analytical in-house packed 50 mm ID, 12 cm long
Pico Frit column ﬁlled with 3 mm C18 silica particles, and gradient separation was
started at 100 nL/min. A binary gradient was used for peptide elution. The mobile
phase A consisted of water/acetonitrile/formic acid/TFA (97.9:2:0.09:0.01 v/v/v/v),
while the mobile phase B consisted of water/acetonitrile/formic acid/TFA
(29.9:70:0.09:0.01 v/v/v/v). Gradient conditions were 5% (v/v) B to 45% (v/v) B in
25 min. After 5 min at 95% (v/v) B, the column was re-equilibrated at 5% (v/v) B for
20 min before the next injection.
MS detection was performed on a QSTAR XL hybrid LC-MS/MS from Applied
Biosystems (Foster City, CA), operating in positive ion mode with electro-spray
potential at 1800 V, curtain gas at 15 units and collisionally activated dissociation
(CAD) gas at 3 units. Information dependent acquisition (IDA) was done by selecting
the four most abundant peaks for analysis after a full time of ﬂight (TOF)-MS scan
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MS was 25 counts. MS/MS analysis was performed in enhanced mode (3 s/scan).
Data were searched on the Mascot search engine (www.matrixscience.com)
against the SwissProt database using the following parameters: MS tolerance
100 ppm; MS/MS tolerance 0.3 Da; ﬁxed modiﬁcations carbamidomethyl cysteine;
variable modiﬁcations methionine oxidized; enzyme trypsin; maximum missed
cleavages 2; taxonomy human.
2.6. Physicochemical characterization of TSH-nanliposomes
The physicochemical properties of TSH-nanoliposomes were characterized us-
ing a Zetasizer Nano ZS (Malvern Instruments Ltd., Worchestershire, United
Kingdom) as previously reported [7]. Brieﬂy, samples were diluted 1:50 in isotonic
saline solution (NaCl 0.9%w/v) to avoidmultiscattering. The average size and narrow
size distribution was measured using photon correlation spectroscopy. The instru-
ment was equipped with a 4.5 mW laser diode operating at 670 nm. Scattered
photons were detected at 173 . The third-order cumulant ﬁtting autocorrelation
function was applied to achieve mean sizes and size distribution proﬁles from
scattered photon patterns. The following parameters were used: real refractive in-
dex 1.59, imaginary refractive index 0.0, medium refractive index 1.330, medium
viscosity 1.0 mPa  s and medium dielectric constant 80.4. The zeta potential was
measured using the Doppler laser anemometry. The apparatus was equipped with a
He/Ne laser doppler anemometry (633 nm) with nominal power of 5.0 mW. A
Smoluchowsky constant F (Ka) of 1.5 was applied during analysis. For each sample
ﬁve measurements were taken with 15 runs per measurement. Results are the
average  standard deviation.
For freeze fracture electron microscopy analysis, samples were centrifuged at
30,000  g for 30 min at room temperature (Microcentrifuge Ole Dich. Denmark),
impregnated with 30% (v/v) glycerol, and then frozen in partially solidiﬁed Freon 22.
The samples were freeze fractured in a freeze fracture device (105 C, 10-6 mm Hg)
and replicated by evaporation from a platinum/carbon gun. The replicas were
extensively washed with distilled water, picked up onto Formvar coated grids and
examined with a Philips CM 10 transmission electron microscope, as previously
reported [25].
2.7. Cell culture
To evaluate the selectivity of the TSH-nanoliposomes against cells expressing
the TSHr, CHO wild type cells without TSHr (CHO-w) and CHO cells transfected with
TSHr (CHO-t) were used. TSHr transfection was performed as previously reported
[26]. CHO cells were incubated (Guaire TS Autoﬂow Codue Water-Jacketed-
Incubator) with F12 medium containing penicillin (100 UI/mL), streptomycin
(100 mg/mL) and FBS (10%, v/v). FTC-133 human thyroid carcinoma cells were
incubated with DMEM/F12 (1:1 v/v) supplemented with glutamate, D-glucose, py-
ruvate, 10% FBS (v/v), penicillin (100 UI/mL), and streptomycin (100 mg/mL). The
medium was replaced every 48 h.
2.8. Intracellular accumulation of TSH-nanoliposomes
The intracellular accumulation of radiolabeled [3H]CHE TSH-nanoliposomes and
control nanoliposomes in CHO-w cells (do not express TSHr) and CHO-t cells (ex-
press TSHr) was measured as a function of time. [3H]CHE was used at a concen-
tration of 0.003% v/v, which corresponds to 3 nmol of [3H]CHE. Cells were plated in
6-well culture dishes (5  105 cells/ml) and successively treated with 100 ml of
tritiated nanoliposomes. Free TSH (0.1-1000 mU/mL) was used in order to investigate
competitive binding to the hormone receptor. After a 3 h incubation period, cells
were centrifuged (1200 rpm at room temperature for 10 min) and the culture me-
dium was removed. Cells were washed twice with phosphate buffered saline (PBS)
and transferred into polypropylene liquid scintillation vials (SigmaeAldrich Chemie,
GmbH, Steinheim, Germany). Cells were then dissolved in a quaternary ammonium
hydroxide solution (2 mL, BTS-450, Beckman Instruments, Inc., Fullerton,
Netherlands) under continuous shaking for 1 h at 60 C, using an incubator shaker
(Innova 4300, New Brunswick Scientiﬁc, Edison, NJ, USA). At the end of the in-
cubation time, the liquid scintillation cocktail (7 mL, Ready Organic, Beckman
Coulter Inc., Fullerton, USA) was added to the solution and the samples were
vigorously mixed and analyzed using a Wallac Win Spectral 1414 liquid scintil-
lation counter (PerkinElmer Life and Analytical Sciences, Inc. Waltham, MA, USA).
1414 Win Spectral Wallac LCS Software was used for data analysis.
2.9. Confocal laser scanning microscopy
The intracellular uptake of ﬂuorescein-labeled TSH-nanoliposomes was
measured in CHO and FTC-133 cells using confocal laser scanning microscopy
(CLSM). Cells (4  105 cells/ml) were placed in 6-well culture plates with culture
medium and a sterile glass slide was positioned in each well. Plates were incubated
for 24 h followed by treatment with ﬂuorescein-labeled nanoliposomes for 2 h. Each
well was thenwashed with PBS (3 times) to remove excess nanoliposomes and cells
were ﬁxed on a sterile glass slide, using 1 mL of an ethanol solution (70%, v/v). Each
slidewaswashed againwith PBS (3 times) and treatedwith 1mL of Hoechst solution
(1/1000), incubated for 5 min and thenwashed with PBS (3 times, 2 mL). Plates were
stored at 4 C prior to CLSM analysis. CLSMwas carried out using a Leika TCS SP2MPCLSM operating at lexc ¼ 496 nm and lem ¼ 519 nm for the FITC probe and at
lexc ¼ 405 nm and lem ¼ 460 nm for the Hoechst probe. A scan resolution of
4096 4096 pixels with an Ar/Kr laser beam of 75 mW, equipped with a ﬂuorescein
analyzer ﬁlter, was used for imaging. Samples were recorded with a macro devel-
oper software package with multi-dimensional series acquisition and direct access
digital control knobs. An immersion oil lens of 63 was used.
2.10. In vitro anticancer activity
The in vitro anticancer activity of free gemcitabine and gemcitabine-loaded
nanoliposomes or TSH-nanoliposomes was evaluated using a MTT assay. Cells
were plated into 96-well culture dishes (5103 cells/0.2 mL) and incubated for 24 h.
Cells were then treated with free drug or nanoliposomes (8 wells/group) and
incubated for 24 h, 48 h or 72 h. Untreated cells were used as a control. Cells were
then incubated for 3 h in tetrazolium salt dissolved in PBS solution (10 mL, 5 mg/mL).
The mediumwas removed and formazan crystals, which precipitated at the bottom
of the well after mitochondrial oxidation, were dissolved with 200 mL of a DMSO/
ethanol mixture (1:1, v/v) and mixed for 20 min at 230 rpm (IKA KS 130 Control,
IKA WERKE GMBH & Co., Staufen, Germany). The solubilized formazan crystals
were quantiﬁed with a microplate spectrophotometer (Multiskan MS 6.0, Labsys-
tems) at a wavelength of 540 nm with a reference wavelength of 690 nm. The
percentage of viable cells was calculated according to the following equation:
Cell viabilityð%Þ ¼ AbsT=AbsC  100
where AbsT is the absorbance of the treated cells and AbsC is the absorbance of
control (untreated) cells. The mean cell viability  standard deviation was derived
from six independent experiments.
2.11. Intracellular uptake of gemcitabine
CHO-w and CHO-t cells were seeded in 12-well plates (3  104 cells/mL) and
incubated with free gemcitabine, gemcitabine-loaded TSH-nanoliposomes or
gemcitabine-loaded untargeted nanoliposomes at a ﬁnal concentration of 1 mM. At
various time points, the cells were scraped from the wells, collected and centrifuged
(1200 rpm, 10 min, 22 C). The pellets were then resuspended in PBS (1 mL) and
disrupted by sonication (SONOPOLUS GM 70, Bandelin Electronic, Berlin, Germany)
at 50 cycles per second for 3 min. The intracellular amount of gemcitabine was
determined by LC. The mean was calculated from ﬁve independent experiments.
Each sample was prepared for LC analysis by adding a 2% (w/v) zinc sulfate solution
(1.4 mL) in a methanol/water mixture (30:70 v/v). The solutionwas vortex mixed for
5 min and then centrifuged at 6000 rpm with an Eppendorf Megafuge centrifuge
(BJB Labcare Ltd., Buckinghamshire, United Kingdom). The supernatant was ﬁltered
through a nylon membrane with a pore size of 0.22 mm (Whatman Inc.), lyophilized,
dissolved in 100 mL of the mobile phase and subjected to LC analysis.
2.12. LC quantiﬁcation
LC analysis was performed using a system from Varian Inc. (Palo Alto, CA, USA),
composed of a 200-2031 Metachem online degasser, a M210 binary pump, a ProStar
410 autosampler, a G1316A thermostat column compartment and a 25 mL CSL20
Cheminert Sample Loop injector. Data was acquired and processed with a Galaxie
chromatography manager software (Varian Inc.). Chromatographic separation was
carried out at room temperature using a GraceSmart RP C18 column (4.6  250 mm,
5 mm particle size, Alltech Grom GmbH, Rottenburg-Hailﬁngen, Germany). The
mobile phase was water/acetonitrile (95:5 v/v). The ﬂow rate was 1 mL/min and
detection was performed at wavelength of 269 nm.
Quantiﬁcation of gemcitabine was done using a standard curve in the linear
concentration range of 0.1 ng/mL to 10 mg/mL. The amount of gemcitabine was
determined according to the following equation:
AUC ¼ 0:60112xþ 0:02840
where x is the drug concentration (mg/mL) and AUC the area under the curve
(mAu  min).
2.13. Animals
In vivo experiments were performed according to the principles and procedures
outlined by the local Ethical Committee and the European Communities Council
Directive of 24 November 1986 (86/609/EEC). Animals were maintained at standard
temperature (20  2 C) and humidity (65%) conditions with 12 h light/12 h dark
cycles and food and water ad libitum. Wistar rats and nonobese diabetic/severe
combined immunodeﬁciency (NOD/SCID) mice were purchased from Harlam (Italy
s.r.l. San Pietro al Natisone (UD), Italy).
2.14. In vivo biodistribution
Biodistribution experiments were performed in femaleWistar rats (4e5months
old, 200e250 g). [3H]CHE-radiolabeled (0.003% v/v corresponding to 3 nmol of [3H]
CHE) nanoliposomes were injected through the tail vein (200 mL). After 3 h, the rats
were sacriﬁced by cervical dislocation and organs were collected. Organs were
Fig. 1. Preparation and physicochemical characterization of thyroid-stimulating hormone (TSH)-nanoliposomes. (a) Schematic representation of TSH conjugation to the surface of
nanoliposomes. (I) The 3-(2-pyridyldithio)propionate (PDP)-moieties present on the surface of the unilamellar vesicles were reduced using dithiothreitol (DTT), resulting in the
formation of vesicles with eSH groups on their surface. (II) TSH-nanoliposomes were formed through the conjugation of TSH with eSH functional moieties on the lipid surface. (b)
Mean size and size distribution of TSH-nanoliposomes measured with photon correlation spectroscopy. (c) Zeta potential analysis of nanoliposomes. (d) Freeze-fracture trans-
mission electron microscopy of TSH-nanoliposomes. DPPC, 1,2-dipalmitoyl-sn-glycero-3-phospocholine monohydrate; DSPE-mPEG2000, N-(carbonyl-methoxypolyethylene glycol-
2000)-1,2-distearoyl-sn-glycero-3-phospho-ethanolamine; DSPE-mPEG2000-PDP, 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[PDP(methoxypolyethylene glycol-2000)].
D. Paolino et al. / Biomaterials 35 (2014) 7101e71097104transferred into polypropylene liquid scintillation vials (SigmaeAldrich Chemie,
GmbH, Steinheim, Germany) and mixed with a quaternary ammonium hydroxide
solution (2 mL) (BTS-450, Beckman Instruments, Inc., Fullerton, Netherlands) under
continuous shaking for 4 h at 60 C using an incubator shaker (Innova 4300, New
Brunswick Scientiﬁc, Edison, NJ, USA) to allow complete dissolution. Samples were
then decolorized with 2 mL of 24% (v/v) H2O2 at room temperature for 5 min. The
liquid scintillation cocktail (7 mL) (Ready Organic, Beckman Coulter Inc., Fullerton,
USA) was then added to the vials and the solution was vigorously mixed. The
samples were analyzed using a Wallac Win Spectral 1414 liquid scintillation
counter (PerkinElmer Life and Analytical Sciences, Inc. Waltham, MA, USA). 1414
Win Spectral Wallac LCS Software was used for data analysis. To correct for radio-
activity derived from the blood, macrophages and capillary endothelial cells in the
organs, a correction was made according to the following equation:
Xtissue ¼ Xorgan  ðV0  CtÞ
where Xtissue represents the corrected radioactivity; Xorgan represents the level of
radioactivity recovered from the organ samples; V0 stands for the total volume of the
vascular space and interstitial ﬂuid, as determined by the radioactivity level in the
whole organ sample divided by the blood concentration 10 min after i.v. injection of
[3H]CHE-labeled nanoliposomes; and Ct represents the blood concentration at the
indicated time. A further quenching correction factor was obtained by measuring
the radioactivity of tissue samples from untreated rats spiked with known amounts
of [3H]CHE (0.030 mCi/mmol lipids).
2.15. In vivo anticancer efﬁcacy and tumor accumulation
FTC-133 cells (1  106 cells/mL) were cultured using a previously reported
protocol [27] and diluted into 200 mL of sterile isotonic PBS (Harlan Italy S.r.l., San
Pietro al Natisone (UD), Italy). The cells were injected subcutaneously into female
NOD SCID mice (4e6 weeks old, 20e22 g) and treatment was initiated when theaverage tumor volume reached w500 mm3 (w8e10 mm in diameter). Mice were
divided into the following ﬁve treatment groups (5 mice/group): PBS, gemcitabine,
gemcitabine-loaded nanoliposomes, and gemcitabine-loaded TSH-nanoliposomes.
Free gemcitabine and both formulations containing gemcitabine nanoliposomes
were administered intravenously (200 mL) at a gemcitabine dose of 5 mg/kg/day for
14 days. The tumor volumewas measured every two days according to the following
equation:
Vt ¼ 0:5 D d2
where Vt is tumor volume,D and d are the long and short tumor diameter. Micewere
sacriﬁced and tumors were collected 15 days after treatment initiation.
Tumor accumulation studies were performed using the same tumor model as in
the anticancer efﬁcacy studies. When the average tumor volume reached
w500 mm3 (w8e10 mm in diameter), mice were injected through the tail vein
(200 mL) with [3H]CHE-radiolabeled (0.003% v/v corresponding to 3 nmol of [3H]
CHE) TSH-nanoliposomes and control nanoliposomes. Mice were sacriﬁced at 1 h,
2 h, 8 h or 24 h post-injection. At each time point, the tumors from three mice per
group were processed and analyzed as described in the in vivo biodistribution
section.3. Results and discussion
3.1. Synthesis and assembly of TSH-nanoliposomes
TSH-nanoliposomes were prepared by conjugating the amino
acid residue of cysteine in the TSH hormone with a thiol-
activated moiety present on the surface of the nanoliposome,
Fig. 2. Evaluation of the selectivity of TSH-nanoliposomes for TSH-receptor (TSHr)-expressing cells. Uptake of [3H]CHE-radiolabeled TSH-nanoliposomes and un-conjugated
nanoliposomes in chinese hamster ovary (CHO) cells without (CHO-w) (a) and with (CHO-t) the TSHr (b). (c) Competitive binding experiments in CHO-t cells using [3H]CHE-
radiolabeled TSH-nanoliposomes and control nanoliposomes in the presence of free TSH. (d) Confocal laser scanning microscopy of ﬂuorescein-labeled TSH-nanoliposomes and
control nanoliposomes after 2 h of incubation with CHO-w and CHO-t cells. Filter: Hoechst ﬁlter (DAPI) (A), FITC ﬁlter (B) and overlay (C). (e) 3D visualization of CHO-t cells after 2 h
of incubation with TSH-nanoliposomes (upper two micrographs) and corresponding 3D visualization following a 180 rotation. Autoﬂuorescence was not observed.
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conjugate was conﬁrmed with LC-MS/MS (Supplementary
Figs. S1 and S2). A small aliquot of pure TSH was digested and
analyzed to generate a list of TSH speciﬁc peptides detectable by
mass spectrometry. A database search of MS/MS data allowed for
high-conﬁdence identiﬁcation of four speciﬁc peptides, three of
which belonged to the alpha-subunit and one of which belonged
to the beta-subunit (Supplementary Table S1). Selected ion
chromatograms (SICs) for two out of the four peaks could be
detected in the nanoliposome sample, whereas none of the peaks
were present in the control sample. The amount of TSH peptide
recovered from the nanoliposome surface was probably below
the detection limit for the two peaks that did not show up during
analysis. Supplementary Figs. S1 and S2 show SICs of those m/z
giving a positive signal, which were ions at m/z 419.73 (peptide
VTVMGGFK, belonging to alpha-chain of the TSH) and 688.32
(peptide ALSQDVCTYR, belonging to the beta-chain of the TSH).
Moreover, the MS/MS spectrum acquired under the peak in data-
dependent mode (Supplementary Figs. S1c and S2c) strongly
resembles that of the MS/MS spectrum acquired from standard
human TSH (Supplementary Figs. S1d and S2d). The dataindicates that TSH was successfully conjugated to the surface of
nanoliposomes.
3.2. Physicochemical characterization of TSH-nanoliposomes
A small size and a narrow size distribution is desired for
colloidal drug delivery systems [28,29]. Here, photon correlation
spectroscopy showed that the untargeted nanoliposomes and
the TSH-nanoliposomes had a mean diameter of 141.8 nm
(Supplementary Fig. S3) and 148.2 nm (Fig 1b), respectively. The
small size increase following TSH conjugation suggests that thy
hydrodynamic radius was increased due to the presence of an
additional hydrophilic molecule on the liposomal surface.
Furthermore, freeze-fracture transmission electron microscopy
was performed to conﬁrm the size-range of the particles
(Fig. 1d). Gemcitabine-loaded nanoliposomes were not sepa-
rately characterized, as it has previously been show that gem-
citabine encapsulation does not affect the mean size and size
distribution of vesicular carriers [30]. Both targeted and untar-
geted formulations exhibited a narrow size distribution (Fig 1b
and Supplementary Fig. S3). The addition of TSH to the
Fig. 3. In vivo biodistribution and thyroid uptake of TSH-nanoliposomes in Wistar rats. (a) Biodistribution of [3H]CHE-radiolabeled TSH-nanoliposomes and control nanoliposomes.
The nanoliposomes were injected through the tail vein of Wistar rats and various organs were collected 6 h after injection. (b) Quantiﬁcation of nanoliposomes in the thyroid.
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sicular carrier, resulting in a reduction of the zeta potential
from 15 mV to 34 mV (Fig. 1c).3.3. Intracellular uptake and in vitro cytotoxicity of TSH-
nanoliposomes
The selectivity of TSH-nanoliposomes for cells expressing the
TSHr was evaluated in wild-type CHO cells lacking the TSHr (CHO-
w) and in CHO cells transfected with the TSHr (CHO-t). [3H]CHE-
radiolabeled TSH-nanoliposomes displayed enhanced cellular up-
take in CHO-t cells in comparison to CHO-w cells, while the uptake
of untargeted nanoliposomes was similar in both cell lines (Fig. 2a
and b). Experiments evaluating the competitive binding of free TSH
and nanoliposomes with TSHr on the cell surface were carried out
using increasing doses of TSH (Fig. 2c). In the case of TSH-
nanoliposomes, the cellular uptake in CHO-t cells decreased as
the dose of free TSH increased, while the cellular internalization of
unconjugated nanoliposomes was independent of free TSH.
Accordingly, confocal laser scanning microscopy showed that ﬂu-
oresceine-labeled TSH-nanoliposomes were internalized to a
greater extent in CHO-t cells, as compared to untargeted nano-
liposomes (Fig. 2d). These ﬁndings demonstrate the active targeting
ability of the TSH-nanocarrier on the cellular level.
The cytotoxicity of empty TSH-nanoliposomes and control
nanoliposomeswas evaluated in CHO cells. The results indicate that
the empty delivery system does not reduce cell viability
(Supplementary Fig. S4). The cell viability remained over 95%, evenwhen the empty nanoliposome was administered at high concen-
trations, demonstrating the in vitro biocompatibility of the delivery
system.
3.4. Comparative biodistribution of TSH-nanoliposomes and control
nanoliposomes
The comparative biodistribution of [3H]CHE-radiolabeled TSH-
nanoliposomes and control nanoliposomes in Wistar rats was
evaluated. The results demonstrate a three-fold increase in the
accumulation of the TSH-nanoliposomes in the thyroid, as
compared to the untargeted nanoliposomes (Fig. 3). The conjuga-
tion of TSH to the liposomal surface did not increase the accumu-
lation of nanoliposomes in other organs, including the liver, spleen,
heart, lungs and kidney (Fig. 3), thus demonstrating in vivo selec-
tivity for the TSHr in the thyroid gland.
3.5. In vitro anticancer efﬁcacy of gemcitabine-loaded TSH-
nanoliposomes
Next, TSH-nanoliposomes were evaluated as drug delivery sys-
tems for gemcitabine, an anticancer drug widely investigated as a
candidate for liposomal delivery [15,16,27,30e32]. The cytotoxicity
of this chemotherapeutic agent was examined in vitro in CHO cells,
which were transfected with TSHr and in FTC-133 cells, which
endogenously express TSHr. In general, gemcitabine-loaded nano-
liposomes displayed greater anticancer efﬁcacy to that of the free
drug (Fig. 4 and Supplementary Fig. S4). In CHO-w cells there was
Fig. 4. Anticancer efﬁcacy of gemcitabine (GEM)-loaded TSH-nanoliposomes in FTC-133 cells expressing the TSHr. (a) Time and dose-dependent effects of free GEM, GEM-loaded
TSH-nanoliposomes and GEM-loaded control nanoliposomes in FTC-133 cells. (b) Competitive binding experiments in FTC-133 with [3H]CHE-radiolabeled TSH-nanoliposomes and
control nanoliposomes in the presence of free TSH. (c) Confocal laser scanning microscopy of FTC-133 cell incubated for 2 h with ﬂuorescein-labeled nanoliposomes. Filters: Hoechst
ﬁlter (DAPI) (A), FITC ﬁlter (B) and overlay (C). (d) 3D visualization of FTC-133 cells after 2 h of incubation with TSH-nanoliposomes (upper two micrographs) Corresponding 3D
visualization following a 180 rotation (lower three micrographs). (e) Intracellular uptake of GEM encapsulated in TSH-nanoliposomes or control nanoliposomes. CPM, counts per
minute.
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loaded targeted or untargeted nanoliposomes (Supplementary
Fig. S4). However, in CHO-t cells the TSH-nanoliposomes out-
performed the control nanoliposomes, in terms of reducing cell
viability. For instance, after 72 h at a concentration of 1 mM gem-
citabine, cells incubated with targeted nanoliposomes and untar-
geted nanoliposomes had a cell viability of w28% and w56%,
respectively (Supplementary Fig. S4). Similarly, in FTC-133 cells,
after 48 h at a concentration of 0.1 mM gemcitabine, cells incubated
with TSH-nanoliposomes and control nanoliposomes had a cell
viability of 11% and 36%, respectively (Fig. 4a). In this context, it was
also demonstrated that the conjugation of TSH to nanoliposomes
increased their intracellular uptake in FTC-133 cells (Fig. 4bed).
Accordingly, the intracellular concentration of gemcitabine also
increased when targeted nanoliposomes were used as a delivery
vehicle in comparison to untargeted nanoliposomes (Fig. 4e).
Moreover, the intracellular accumulation of TSH-nanoliposomes
decreased as the concentration of free TSH increased in the me-
dia (Fig. 4b). Competitive binding with the free ligand conﬁrms that
the major mechanism for cellular internalization is mediated by
binding of the delivery system to TSHr. The results demonstrate
that the conjugation of TSH can markedly improve the anticancer
efﬁcacy of gemcitabine-loaded nanoliposomes in cells expressing
TSHr.3.6. In vivo anticancer activity and tumor accumulation of
gemcitabine-loaded TSH-nanoliposomes
A subcutaneous tumor model of follicular thyroid carcinoma
(FTC-133 cells) was used to evaluate the in vivo anticancer efﬁcacy
of gemcitabine-loaded TSH-nanoliposomes. The nanoliposomes
were radiolabeled ([3H]CHE) to measure tumor accumulation upon
intravenous injection. As is evident from Fig. 5a, the presence of the
TSH on the liposomal surface allowed for increased accumulation of
the delivery vehicle in the tumor. For instance, 1 h post adminis-
tration, the TSH-nanoliposomes were present in the tumor at an
almost two-fold higher level than the unconjugated nano-
liposomes. Furthermore, the in vivo anticancer activity of
gemcitabine-loaded nanoliposomes was evaluated. Gemcitabine-
loaded TSH-nanoliposomes elicited the greatest reduction in tu-
mor growth. Indeed, after 14 days of treatment, a signiﬁcant dif-
ference in tumor volume and weight was evident between groups
receiving gemcitabine-loaded TSH-nanoliposomes or gemcitabine-
loaded control nanoliposomes (Fig. 5b and c). The anticancer efﬁ-
cacy is further illustrated in photographs of dissected tumor sam-
ples (Fig. 5d).
Taken together, the results demonstrate that TSH-
nanoliposomes are an effective delivery platform for targeting
thyroid tissue in vivo. We envision that TSH-nanoliposomes could
Fig. 5. In vivo anticancer efﬁcacy and tumor accumulation of TSH-nanoliposomes in a tumor model of follicular thyroid carcinoma (FTC-133 cells). (a) In vivo tumor uptake of [3H]-
CHE radiolabeled TSH-nanoliposomes and control nanoliposomes (n ¼ 3/group/time point). Statistical analysis was performed by one-way ANOVA and p < 0.001 (*) was considered
statistically signiﬁcant with respect to the accumulation of control nanoliposomes. (b) Tumor volume as a function of treatment with GEM-loaded TSH-nanoliposomes and control
nanoliposomes (n ¼ 5/group). Statistical analysis: *, p < 0.01 vs. control; **, p < 0.001 vs. control; ##, p < 0.001 vs. GEM-loaded nanoliposomes. (c) Weight of tumors 15 days after
treatment initiation (n ¼ 5/group). Statistical analysis: *, p < 0.001 vs. control; ##, p < 0.001 GEM-loaded nanoliposomes. (d) Photographs of dissected tumors 15 days after
treatment initiation.
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both hydrophilic and hydrophobic therapeutics can be loaded
inside liposomes [33e36]. For instance, TSH-nanoliposomes could
also be used for the delivery of antithyroid drugs to benign le-
sions, such as thyroid hyper-functioning adenomas [37].4. Conclusions
We have developed a nanodelivery system consisting of nano-
liposomes conjugated to the TSH. This delivery system is designed
to target cells expressing the TSHr, which is frequently found in
normal thyroid tissue and in a large number of thyroid carcinomas.
Indeed, TSH-nanoliposomes displayed increased cellular uptake in
comparison to control nanoliposomes in cells with TSHr. In addi-
tion, targeted nanoliposomes had higher levels of accumulation in
normal thyroid tissue and in subcutaneous thyroid tumors.
Furthermore when TSH-nanoliposomes were loaded with gemci-
tabine the in vitro and in vivo anticancer efﬁcacy was markedly
improved. Herein, we have demonstrated a valid delivery platform
for obtaining enhanced deposition of drugs in thyroid tissue
following systemic injection.Conﬂict of interest disclosure
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